Riitta Veijola at University of Oulu and Oulu University Hospital - Research Interests, Publications & Academic Profile

Riitta Veijola

Professor and Chief Physician in Paediatrics

Oulu University Hospital

Finland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Vietnamese students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

70%

Biostatistics

20%

Islet Biology

60%

Diabetology

60%

Pediatric Endocrinology

50%

Insulin Resistance

40%

Immunogenetics

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Identification of monogenic variants in more than ten per cent of children without type 1 diabetes-related autoantibodies at diagnosis in the Finnish Pediatric Diabetes Register

Article Link

Year:

2023

Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children

Article Link

Year:

2023

Detection of enterovirus RNA in peripheral blood mononuclear cells correlates with the presence of the predisposing allele of the type 1 diabetes risk gene IFIH1 and with disease stage

Article Link

Year:

2022

Heterogeneity in the presentation of clinical type 1 diabetes defined by the level of risk conferred by human leukocyte antigen class II genotypes

Article Link

Year:

2022

Impacts of Data Synthesis: A Metric for Quantifiable Data Standards and Performances

Article Link

Year:

2022

HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children

Article Link

Year:

2022

Viral infection-related gene upregulation in monocytes in children with signs of β-cell autoimmunity.

Article Link

Year:

2022

Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years: A follow‐up study of two open‐label, randomized controlled trials

Article Link

Year:

2022

INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA)

Article Link

Year:

2022

Extended family history of type 1 diabetes in HLA ‐predisposed children with and without islet autoantibodies

Article Link

Year:

2020

Collaborators16

Päivi H. Tossavainen

FINLAND

Juha Röning

Professor

University of Oulu

FINLAND

Amir-Babak Sioofy-Khojine

University of Tampere

FINLAND

Paula Vähäsalo

FINLAND

Jarno Kettunen

Helsinki University Hospital

FINLAND

Sarah Richardson

Associate Professor in Cellular Biomedicine

University of Exeter

UNITED KINGDOM

Elísabet Einarsdóttir

Karolinska Institutet

SWEDEN

Mikael Knip

Professor

University of Helsinki

FINLAND

Tiinamaija Tuomi

University of Helsinki

FINLAND

Päivi Miettinen

University of Helsinki

FINLAND

Mark Peakman

King’s College London

UNITED KINGDOM

sami oikarinen

University of Tampere

FINLAND

Harri Niinikoski

Professor

University of Turku

FINLAND

Markus Mattila

University of Tampere

FINLAND

Mikko Lehtovirta

University of Helsinki

FINLAND

Jorma Ilonen

Professor

University of Turku

FINLAND

How do Vietnamese students reach out?

Meet Kite AI